3D Health Solutions

Executive Summary

3D Health Solutions (3DHS) is a San Diego-based biotechnology company specializing in canine organoid cell culture for therapeutic nutrition and pharmaceutical screening. Founded in 2015, the company has developed proprietary 3D cell models representing multiple organs including intestine, liver, pancreas, kidney, and heart. These organoids enable more physiologically relevant testing of nutritional interventions and drug candidates compared to traditional 2D cell cultures or animal models, potentially reducing costs and improving predictivity in veterinary medicine. 3DHS offers research services and co-develops custom models for partners, positioning itself as a key enabler in the growing field of precision medicine for companion animals. The market for canine health products and veterinary pharmaceuticals is expanding rapidly, driven by increased pet ownership and demand for advanced therapies. By providing a platform that can accelerate discovery and reduce attrition in drug development, 3DHS addresses a critical bottleneck. While the company is private and early-stage, its technology has the potential to disrupt traditional screening methods. Key upcoming milestones include formal validation studies, partnership announcements, and expansion of its organoid portfolio. If successful, 3DHS could become a standard tool for veterinary drug developers and nutraceutical companies, capturing significant market share in the canine health sector.

Upcoming Catalysts (preview)

• Q2 2026Publication of validation data in peer-reviewed journal70% success
• TBDStrategic partnership with major veterinary pharmaceutical company50% success
• Q4 2026Launch of commercial drug screening service60% success